Caixin
Aug 20, 2022 02:23 AM
BUSINESS

Pfizer Signs China Partnership to Make Paxlovid Covid Pills Locally

Approved in the U.S. for emergency use, Paxlovid has been cleared for Covid-19 treatment in 70 countries and regions globally.
Approved in the U.S. for emergency use, Paxlovid has been cleared for Covid-19 treatment in 70 countries and regions globally.

Chinese drugmaker Zhejiang Huahai Pharmaceutical Co. Ltd. has entered an agreement with Pfizer Inc. to manufacture the U.S. giant’s Covid-19 pill Paxlovid in China.

Shanghai-listed Huahai Pharmaceutical said Thursday that it has signed a non-exclusive production and supply agreement with the Chinese subsidiary of Pfizer. Under the agreement, Huahai Pharmaceutical will produce Paxlovid in China for five years.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin China Biz Roundup: China Warns Not to Bet Against the Yuan
00:00
00:00/00:00